Jubilant Pharmova soars as its arm receives USFDA`s approval for Technetium Sulfur Colloid Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Jubilant Pharmova is currently trading at Rs. 435.25, up by 22.85 points or 5.54% from its previous closing of Rs. 412.40 on the BSE.
The scrip opened at Rs. 420.00 and has touched a high and low of Rs. 439.80 and Rs. 415.00 respectively.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 484.55 on 01-Sep-2023 and a 52 week low of Rs. 268.80 on 29-Mar-2023.
Last one week high and low of the scrip stood at Rs. 439.80 and Rs. 392.60 respectively. The current market cap of the company is Rs. 6568.75 crore.
The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 24.84% and 24.48% respectively.
Jubilant Pharmova’s wholly owned subsidiary -- Jubilant Draximage Inc has received approval from the United States Food and Drug Administration (USFDA) with regards to the company’s abbreviated new drug application (ANDA) submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C) for kit for the preparation of Technetium (Tc 99m) Sulfur Colloid Injection. For this approval, Jubilant is eligible for 180 days of exclusivity through the ‘Competitive Generic Therapy’ designation from the USFDA.
